Press Enter to search · Esc to close
As GLP-1 demand outpaces supply, fresh data from Karachi, a critical review of Asian-descent dosing, and an early trial of a novel Chinese molecule hint at a more personalized future for metabolic care.
A small real-world study suggests older, cheaper anti-obesity pills may help preserve much of the weight loss achieved on a year of GLP-1s — a practical lifeline as access and prices stay volatile.
The same peptide class everyone's whispering about in the locker room is showing up in neurology, nephrology, and orthopedic data. The signal looks real — but moderate, not miraculous.
Semaglutide and liraglutide are quietly migrating from diabetes clinics into stem-cell labs and rare-disease wards — even as a social-media-driven shortage exposes the cost of off-label demand.
A new meta-analysis confirms GLP-1 drugs protect the heart and kidneys. Real-world data suggests pairing them with SGLT2 inhibitors may compound the benefit — with caveats worth understanding.
A new wave of population-level research is moving the link between chair-time and cancer from slogan to statistics — and reframing movement as a quiet prevention lever for desk-bound lives.
A real-world analysis tied to the dulaglutide shortage put concrete numbers on what happens to blood sugar in the three months after stopping. The picture is sobering — and worth bringing to your doctor.
The blockbuster weight-loss drug is being studied for far more than the scale. Here's what the newest research actually shows — and where the evidence still thins out.
A new pooled analysis of randomized trials isolates the non-diabetic obesity population — the use case driving most consumer demand — and quantifies what the dual GIP/GLP-1 agonist actually does, and what it costs.
Weekly semaglutide rewrote metabolic medicine. The pipeline behind it — a small-molecule pill, a twin-receptor agonist, and an injectable depot that lasts weeks — is now coming into focus.